Table 1.
Main baseline characteristics of the hepatitis C treated study population.
| Characteristics | Total population (N = 164) | SVR (N = 90) | NR (N = 74) | P (SVR vs. NR) |
|---|---|---|---|---|
| Median age [years (interquartile range)] | 42 (3945) | 41 (38–45) | 43 (39–46) | 0.46 |
| Male sex [n (%)] | 122 (74) | 64 (53) | 58 (47) | 0.29 |
| Median CD4 cell count [cells/μl (interquartile range)] | 468 (345–647) | 456 (327–644) | 504 (371–720) | 0.40 |
| Patients on antiretroviral therapy [n (%)] | 120 (73) | 65 (72) | 55 (74) | 0.74 |
| Median plasma HIV-RNA in patients with no antiretroviral therapy [log copies/ml (interquartile range)] | 3.0 (2.1–3.7) | 3.0 (2.2–3.7) | 3.0 (2.1–3.8) | 0.89 |
| Median serum HCV-RNA [log IU/ml (interquartile range)] | 6.7 (5.9–7.0) | 6.2 (5.4–6.7) | 6.9 (6.6–7.2) | <0.0001 |
| HCV genotypes [n (%)] | ||||
| 1 | 95 (58) | 40 (44) | 55 (74) | <0.0001 |
| 3 | 51 (31) | 43 (48) | 8 (11) | |
| 4 | 18 (11) | 7 (8) | 11 (15) | |
| Median liver fibrosis stiffness [kPa (interquartile range)] | 6.7 (5.0–10.0) | 6.0 (4.8–8.1) | 7.6 (6.0–13.1) | <0.001 |
HCV, hepatitis C virus; NR, nonresponder; SVR, sustained virological response.